Allopurinol and Pathogenesis of Cirrhosis

Allopurinol Interferes With the Pathological Mechanisms of Hepatic Decompensation

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07033533

Enrollment

100

Registered

2025-06-24

Start date

2023-06-01

Completion date

2024-03-01

Last updated

2026-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cirrhoses, Liver

Brief summary

Hepatic decompensation is a common healthcare issue . This study was conducted to investigate how allopurinol can interfere with the pathological mechanisms of HD.

Interventions

DRUGAllopurinol Tablet

allopurinol 300

DRUGPlacebo

placebo tablet

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* age 18-75 both sex

Exclusion criteria

* active GIT bleeding

Design outcomes

Primary

Measure	Time frame	Description
Levels of gut barrier and microbial translocation biomarkers, including zonulin, lipopolysaccharide (LPS), and malondialdehyde (MDA), measured in serum/plasma.	6 MONTHS	Levels of gut barrier and microbial translocation biomarkers, including zonulin, lipopolysaccharide (LPS), and malondialdehyde (MDA), measured in serum/plasma.

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 12, 2026